Status:
COMPLETED
Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19
Lead Sponsor:
Institut Mutualiste Montsouris
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
Hydroxychloroquine and azithromycin have been proposed as treatment of COVID-19 patients, but few reports have assessed this combination therapy in critically ill COVID-19 patients. Many raised conce...
Eligibility Criteria
Inclusion
- critically ill patients admitted in ICU for severe COVID-19 with respiratory failure for at least two days of treatment with hydroxychloroquine and azithromycin.
Exclusion
- cardiac conduction disorders
- continuous anti-arrhythmic therapy
- heart failure
- chronic renal failure
Key Trial Info
Start Date :
March 19 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04452617
Start Date
March 19 2020
End Date
July 1 2020
Last Update
September 1 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Mutualiste Montsouris
Paris, France, 75014